Home › Funds › Layline Advisors, LLC › ABT
Layline Advisors, LLC position in ABT
ABBOTT LABORATORIES · Health Care
Layline Advisors, LLC reported holding 3,681 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$364K, representing 0.36% of its reported portfolio and ranking #39 among its reported holdings. Layline Advisors, LLC has disclosed ABT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-02 · Source: SEC EDGAR Form 13F-HR
How Layline Advisors, LLC's ABT position evolved
Layline Advisors, LLC first disclosed a stake in ABT in Q1 2026 at 3,036 shares (US$312K). The position peaked in Q3 2026 at 3,681 shares, worth US$364K. Across 3 filings, Layline Advisors, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,681 shares valued at US$364K — an increase of 49 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 3.04K | $311.74K | New |
| Q2 2026 | 3.63K | $329.61K | Add |
| Q3 2026 | 3.68K | $363.76K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on Layline Advisors, LLC
FAQ
How long has Layline Advisors, LLC held ABT?
Layline Advisors, LLC has disclosed ABT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Layline Advisors, LLC's current position in ABT?
As of Q3 2026, Layline Advisors, LLC holds 3.68K shares of ABT (ABBOTT LABORATORIES), valued at $363.76K, representing 0.36% of its reported portfolio and ranking #39.
Has Layline Advisors, LLC been buying or selling ABT?
In the latest 13F filing (Q3 2026), Layline Advisors, LLC increased its position in ABT. The position peaked in Q3 2026 at 3.68K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.